ESH MDS 2021 | Key clinical trials in high-risk and low-risk MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses key clinical trials in the field of myelodysplastic syndromes (MDS) at ESH MDS 2021. In low-risk MDS, Prof. Platzbecker highlights a study evaluating imetelstat (NCT02598661) and the COMMANDS study (NCT03682536) comparing luspatercept versus the standard of care (SOC), epoetin alfa (EPO), in low-risk MDS patients. In high-risk MDS, Prof. Platzbecker discusses trials combining novel agents with SOC hypomethylating agents (HMA) with venetoclax, magrolimab or pevonedistat, and the Phase II STIMULUS-MDS1 (NCT03946670) and Phase III STIMULUS-MDS2 studies (NCT04266301) investigating sabatolimab for high-risk MDS. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
